CLINICAL TRIALS: Edited by Neal S. KleimanRecent clinical trials in valvular heart diseasesGoel, Sunny; Ro, Richard; Lerakis, Stamatios; Khera, SahilAuthor Information Division of Cardiology, Department of Medicine, The Mount Sinai Hospital, New York, USA Correspondence to Sahil Khera, MD, MPH, FACC, FSCAI, Associate Director, Structural Heart Program, Assistant Professor of Medicine, The Mount Sinai Hospital / Icahn School of Medicine, 1 Gustave L. Levy Pl, NY 10029, USA. Tel: +1 212 241 4906; fax: +1 212 241 9963; e-mail: email@example.com Current Opinion in Cardiology: July 2020 - Volume 35 - Issue 4 - p 313-318 doi: 10.1097/HCO.0000000000000750 Buy Metrics Abstract Purpose of review In recent years, no other field of cardiology has experienced a greater influx of transformational therapeutic options as valvular heart disease. The present review discusses the landmark trials published in the last 18 months that have shaped the modern day management of valvular heart diseases. Recent findings There have been several landmark trials in recent years, which have expanded the indications for transcatheter aortic valve replacement to low-risk surgical patients and the use of MitraClip for patients with functional mitral regurgitation. Options for transcatheter management of right-sided valvular disease also continue to evolve, including promising results from early feasibility studies. Summary The development of novel transcatheter therapies for valvular heart disease has expanded the armamentarium of physicians treating patients with valvular heart disease. The present review will focus on the recent (within 2 years) trials in this field of interest. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.